SunHo Announces First Patient Dosed in Phase I/II Clinical Trial of a Potential First-in-class Immunocytokine IBB0979

SunHo BioPharmaceutical Co., Ltd. (“SunHo”), a clinical-stage leading biopharmaceutical company in immunocytokines with full-set of capabilities from discovery to commercialization, announced that IBB0979 (B7H3-IL10 immunocytokine), a potential first-in-class immunocytokine developed in-house for th...

SunHo Received U.S. FDA IND Approval to Initiate Phase I Clinical Trials of IBB0979 as Innovative Immunocytokine

On October 28, 2022, SunHo received the IND approval from the U.S. Food and Drug Administration ("FDA") that IBB0979, the worlds first immunocytokine in the same class, has been approved for clinical trials in the treatment of advanced malignant solid tumors. This is the 3rd innovativ...

SunHo Announces First Patient Dosed in Phase 1/2 Clinical Trial of Two First-in-class Immunocytokines: IAP0971 and IAE0972

SunHo BioPharmaceutical Co., Ltd. (“SunHo”), a clinical-stage leading biopharma in immunocytokines with full-set of capabilities from discovery to commercialization, announced that IAP0971 (PD1-IL15 immunocytokine) and IAE0972 (EGFR-IL10 immunocytokine), two first-in-class immunocytokines developed ...

SunHo Will Present Novel TNFR2 Agonist and Antagonist Antibodies as Treg-Teff Modulator for Cancer Immunotherapy at the 2022 AACR Annual Meeting.

TNFR2 has been found to be overexpressed on highly suppressive tumor-infiltrating regulatory T cells (Treg), activated effector T cells (Teff), and many tumor cells in the tumor microenvironment, which makes TNFR2 a novel and very promising target for cancer immunotherapy. Based on the deep understa...

SunHo Wishes You All a Happy New Year and All the Best.

2021 Annual Meeting of SunHo Successfully Held Under the Theme of “Keep Innovating And Pursuit of Excellece”.

SunHo Received U.S. FDA IND Approval to Initiate Phase I Clinical Trial of IAP0971 as Innovative Immunocytokines.

SunHo received the IND approval from FDA to initiate phase I clinical trials of IAP0971. IAP0971 is the first armed PD1-IL15 immunocytokine with IND approval by both FDA and NMPA.

SunHo Received U.S. FDA IND Approval to Initiate Phase I Clinical Trial of IAE0972 as Innovative Immunocytokines.

SunHo received the IND approval from FDA to initiate phase I clinical trials of IAE0972. IAE0972 is the first EGFR-IL10 immunocytokine with IND approval by both FDA and NMPA.